Back to Search
MEAGHAN DOUGHER, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1396495933Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (13)
Contextual control of equivalence-based transformation of functions.
PMID 12144312·J Exp Anal Behav·2002
8-other
Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples.
PMID 17668210·Cancer Chemother Pharmacol·2008
7-preclinical
The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.
PMID 18097562·Int J Oncol·2008
7-preclinical
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
PMID 17657218·Leukemia·2007
7-preclinical
CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
PMID 17160682·Cancer Immunol Immunother·2007
7-preclinical
Transformation of the discriminative and eliciting functions of generalized relational stimuli.
PMID 17970414·J Exp Anal Behav·2007
8-other
Contextual control by function and form of transfer of functions.
PMID 17725053·J Exp Anal Behav·2007
8-other
Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy.
PMID 16465373·Int J Oncol·2006
4-observational
Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
PMID 16397048·Clin Cancer Res·2006
7-preclinical
Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
PMID 15623646·Clin Cancer Res·2004
7-preclinical
Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
PMID 15240546·Clin Cancer Res·2004
7-preclinical
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
PMID 14615373·Blood·2004
7-preclinical
Contextual control of stimulus generalization and stimulus equivalence in hierarchical categorization.
PMID 12507013·J Exp Anal Behav·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3400 SPRUCE ST
PHILADELPHIA, PA 19104 - Phone
- (215) 662-6503
Quick Facts
- NPI
- 1396495933
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 13
Are you this provider?
Claim Your Profile